



Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference

March 27, 2023 at 7:00 AM EDT

DURHAM, N.C.--(BUSINESS WIRE)--Mar. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based *ex vivo* allogeneic CAR T and *in vivo* gene editing therapies, today announced that the Company will participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days taking place April 3-4, 2023.

Details for the company presentation are as follows:

Date: Monday, April 3, 2023

Time: 3:20 PM ET

Location: Lotte New York Palace Hotel

The presentation will be available via a recorded webcast accessible on Precision's website in the Investors section under Events & Presentations: <https://investor.precisionbiosciences.com/events-and-presentations>. An archived replay will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple *ex vivo* "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230327005144/en/): <https://www.businesswire.com/news/home/20230327005144/en/>

Investor and Media Contact:

Mei Burris

Director, Investor Relations & Finance

Mei.burris@precisionbiosciences.com

Source: Precision BioSciences, Inc.